Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NYMOX PHARMACEUTICAL CORPORATION

(NYMX)
SummaryQuotesChartsNewsCompanyFinancials 
Business Summary
Logo Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.

Number of employees : 3 people.
Sales per Business
20192020Delta
Pharmaceutical Products0.12100%0.01100% -95.69%
USD in Million
Sales per region
20192020Delta
United States0.0977.7%0.0063.3% -96.49%
Europe and Other0.0220.8%0.0039.8% -91.74%
Canada0.001.2%0.003.9% -86.64%
USD in Million
Managers
Name Title Age Since
Paul Averback, Dr. Chairman, President & Chief Executive Officer 69 1995
Erik Danielsen Chief Financial Officer 56 -
Randall J. Lanham COO, Secretary, Director & General Counsel 55 -
David S. Morse, Dr. Independent Director 63 2006
James G. Robinson Independent Director 84 2015
M. Richard Cutler Lead Independent Director 62 -
Russell I. Thomson, Dr. Vice President-Quality & Regulatory Affairs - 2020
Members of the board
Name Title Age Since
Paul Averback, Dr. Chairman, President & Chief Executive Officer 69 1995
Randall J. Lanham COO, Secretary, Director & General Counsel 55 -
David S. Morse, Dr. Independent Director 63 2006
James G. Robinson Independent Director 84 2015
M. Richard Cutler Lead Independent Director 62 -
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 78,711,000 43,316,795 55.0% 0 0.0% 55.0%
Shareholders
NameEquities%
Paul Averback 30,508,010 38.8%
James G. Robinson 3,550,550 4.51%
BlackRock Fund Advisors 1,440,204 1.83%
Erik Danielsen 1,182,500 1.50%
Geode Capital Management LLC 301,982 0.38%
The Vanguard Group, Inc. 206,488 0.26%
BlackRock Investment Management LLC 196,926 0.25%
Randall J. Lanham 152,900 0.19%
Teachers Advisors LLC 121,327 0.15%
Charles Schwab Investment Management, Inc. 94,996 0.12%
Company contact information
Nymox Pharmaceutical Corp.
Bay & Deveaux Streets
2nd Floor
Nassau, New Providence

Phone : +1.800.936.9669
Fax : +1.514.332.2227
Web : http://www.nymox.com
Sector Other Biotechnology & Medical Research
Connections : Nymox Pharmaceutical Corporation